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Conclusion The two surgical techniques are both valid 
conservative surgical options for advanced laryngeal can-
cer treatment.
Keywords Systematic review · Meta-analysis · Advanced 
laryngeal carcinoma · Surgical conservative treatment · 
Oncological outcomes.
Introduction
Laryngeal cancer is one of the most common cancer of the 
upper aerodigestive tract and the second among head and 
neck cancers after skin malignancies. Most of laryngeal 
neoplasms show squamous cell carcinoma (SCC) histol-
ogy, accounting for 85–95% of laryngeal malignant tumours 
whose incidence is approximately 11,000–13,000 of cases 
annually in the USA [1].
Advanced T stage (T3–T4) laryngeal cancer, encompass 
a heterogeneous variety of different lesions, each character-
ised by distinct clinical presentation, biological behaviours 
and prognosis. Thus, neoplastic pathways of tumour spread, 
should be carefully considered during therapeutic planning 
[2–4].
Currently, different modalities of treatment are avail-
able for all subtypes of T3 and T4 laryngeal tumours 
and, although oncologic outcome does remain the first 
goal, preservation of laryngeal functions and quality of 
life has progressively gained an important role heavily 
influencing the decision-making process of surgeons [5]. 
Since 1871, when Van Luschka introduced an accurate 
anatomical description of laryngeal framework by set-
ting the body for future laryngeal surgery [6], over the 
last decades, the evolution of the treatment of laryngeal 
cancer has passed through different attitudes and aims, 
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and in this scenario total laryngectomy (TL) has been the 
mainstay of treatment for decades. Afterwards, voice pres-
ervation has gained a crucial role in treatment planning 
and patients’ expectations, consequently, patients have 
progressively begun to undergo surgical and nonsurgical 
preserving therapies [7]. The increasing accuracy of diag-
nostic techniques have gradually ensured a better patient 
selection, thus allowing the introduction of conservative 
surgery procedures in clinical practice. In fact, the propor-
tion of patients receiving TL has declined from 74% in 
1999 to 26% in 2007 [8] and open partial laryngectomy 
(OPL) together with transoral laser microsurgery (TLM), 
have been progressively introduced for the treatment of 
intermediate and advanced laryngeal tumours. Since the 
1970s’ when Labayle and Piquet introduced supracricoid 
partial laryngectomy for glottic cancer treatment [9, 10] 
and Steiner commenced TLM for laryngeal carcinomas in 
1979 [11], laryngeal preservation procedures have paved 
the pathway for the contemporary management of laryn-
geal cancer. However, whereas chemoradiation therapy 
protocols have a tough scientific basis [12–14], indica-
tions for conservative surgery still wait for full validation.
Many publications, indeed, confirming the oncologi-
cal and functional benefits of both OPL and TLM exist, 
and they show that both surgical procedures offer similar 
local control rates and overall survival to total laryngec-
tomy for advanced laryngeal cancer treatment [15, 16], by 
ensuring fair post treatment organ functions when appro-
priate patients selection has been performed. In addition, 
consequently to the increasing use of chemotherapy with 
concurrent radiotherapy organ preservation strategies to 
treat advanced laryngeal cancer, OPLs have established 
an important and oncologically reliable role in the man-
agement of recurrent radio-resistant laryngeal carcinoma 
[17, 18].
In this respect, treatment plan selection might respect 
patients’ needs, by aiming and demanding not only onco-
logical but also functional results, in accordance with sur-
geons’ skills and knowledge.
Given this background, we performed a systematic 
review of English language literature in an attempt to more 
robustly establish the local control and overall survival 
in conservation laryngeal surgery for advanced T stage 
cancers. The objective of this review and meta-analysis 
was to synthesise the oncological outcomes following 
laryngeal surgical preservation protocol, including both 
open partial and transoral laser procedures, performed as 
primary therapeutic options for advanced T3 and T4 laryn-
geal squamous cell carcinoma through the analysis of the 
latest reports in laryngeal cancer management published 
in the past 35 years, to give a full view about the most reli-
able therapeutic options for this type of patients.
Materials and methods
The systematic review was performed using independently 
developed search strategies in literature review methodol-
ogy, and it was written in accordance with PRISMA State-
ment (http://www.prisma-statement.org) [19], to guarantee 
a scientific strategy of research to limit bias by a systematic 
assembly, critical appraisal and synthesis of all the most 
relevant studies published on this topic [20, 21].
The databases interrogated included PubMed Clinical 
Queries http://www.ncbi.nlm.nih.gov. Reference lists from 
identified articles were searched and cross-referenced to 
identify additional relevant articles, and national experts in 
the field were contacted to identify unpublished data.
The search terms included the following various combi-
nations to maximise the yield: advanced (T3–T4) laryngeal 
cancer AND laser; AND open partial laryngectomy (OPL); 
AND transoral laser microsurgery (TLM); AND cordec-
tomy; AND conservative surgery; AND tracheohyoido-
pexy (THIP) or tracheohyoidoepiglotto-pexy (THIEP); AND 
supratracheal partial laryngectomy (STPL); AND supracri-
coid partial laryngectomy (SCPL) ; AND cricohyoidopexy 
(CHP) or cricohyoidoepiglotto-pexy (CHEP).
The search was performed for the first time on January 
2016 and was set to automatically update periodically until 
December 2016.
First, duplicates were removed electronically. Then 
abstracts were reviewed to exclude obviously irrelevant 
articles. Non-English language papers and duplicates were 
excluded. Experimental studies and papers dealing with 
pathologies other than advanced lesions of the larynx were 
excluded.
The inclusion criteria were set a priori and deliberately 
kept wide to encompass as many articles as possible without 
compromising the validity of the results, and they included 
articles: (1) published from 1980 onwards, (2) reporting 
published series of > 10 patients underwent partial laryn-
geal procedures with a minimum of 5 years follow up, (3) 
about conservation laryngeal procedures excluding total lar-
yngectomy, (4) reporting data distinguishes results of partial 
laryngeal procedures divided into: TLM, CHP, CHEP, THIP, 
THIEP, SCL, HPL, Cordectomy, (5) with a clear description 
of TNM tumour stage and treatment selection criteria for 
primary laryngeal SCC, and (6) clear description of local 
control rate at 60 months.
The search excluded articles published before 1980 
because the surgical repertoire until the 1960s was pri-
marily restricted to TL as therapeutic surgical option for 
advanced laryngeal cancer and because reporting outcomes 
on relatively small case series with highly variable local 
control rates and functional outcomes. Furthermore, SCPL, 
although described much earlier, became more popular and 
common in clinical practice since the 1970s. Consequently, 
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we considered articles published starting from the 1980s 
onwards to allow time for the flattening of the learning 
curve, together with the entrance in the surgical practice of 
more technological procedures, such as TLM for supraglot-
tic lesions, which obviously belong to the latest years of our 
analysis.
We filtered the studies to ensure that only data from cen-
tres that had published on at least 10 patients were included 
in the review; this was done as a quality assurance measure 
as there are several case series in the literature, which have 
published the results of small numbers of cases spanning 
several years. Non-English language papers and duplicates 
were excluded.
All data were independently extracted by two authors 
and quality assessed. Eligibility for inclusion was sepa-
rately assessed and when in doubt discussed and decided 
by consensus.
We chose overall survival (OS) and local control rate 
(LC) at 60 months as the primary measure of oncological 
outcome. Possible bias including age, existing co-morbidity, 
access and availability to treatment for other medical condi-
tions and incidence of second primary tumours. Similarly 
disease-free survival (DFS) will depend on the incidence of 
regional and distant metastasis.
Abstracts were analysed to identify papers that fulfilled 
inclusion criteria and a first qualitative and descriptive 
review-analysis of selected articles was carried on; whilst, 
exclusively, publications clearly describing their aim and 
objectives, their inclusion and exclusion criteria, with clear 
or detachable statistical data, reporting adequate survival 
interval at 60 months from conservative surgical primary 
treatment, and well describing the surgical techniques and 
post-operative complications, were included in our meta-
analysis. For articles not reporting raw data, letters were 
sent to the corresponding authors requesting them, otherwise 
they were excluded from the quantitative analysis. Raw data 
from the meta-analysis were entered into the appropriate 
contingency tables to allow calculation of OS and DFS, 
Younden’s index, for each surgical technique: TLM, CHP, 
CHEP, THIP, THIEP, SCL, HPL, Cordectomy.
Given the variable reporting practice, the use of outcome 
measures that cannot be directly compared and the need for 
different search strategy, we did not include functional out-
come in this meta-analysis as a criterion for inclusion.
Study characteristics and quality assessment
All included papers were graded using the NICE scoring 
scale for retrospective case series (Available at: http://www.
nice.org.uk/nicemedia/pdf/Appendix_04_qualityofcase_
series_form_preop.pdf). This is a scoring scale with eight 
items, with each item scoring zero or one based on the study 
methods (Yes = 1; No = 0). Scores of ≥ 6 are considered to 
indicate a good quality study, scores between four and five 
as fair and those studies with a score of three are treated as 
poor quality (Table 1).
Statistical analysis
Fisher’s exact test was used for statistical analysis of categor-
ical data for the descriptive review, and a value of p < 0.05 
was considered significant.
The pooled estimate of each statistic was calculated after 
Freeman–Tukey double arcsine transformation to stabilise 
the variances. A random effect model was specified, using 
the method of DerSimonian and Laird, with the estimate of 
heterogeneity being taken from the inverse-variance fixed-
effect model. Heterogeneity is also quantified using the 
I-squared measure.
Heterogeneity (or absence of homogeneity) of the results 
between the studies is assessed graphically by forest plots 
and statistically using the quantity I2 that describes the per-
centage of total variation across studies that is attributable to 
heterogeneity rather than chance [22, 23]. This is a measure 
of heterogeneity between the studies and ranges from 0 to 
100%; high figures indicate greater heterogeneity in the data.
When studies have low heterogeneity (pragmatically, 
I2 < 25%), the differences between reported outcomes can 
be explained simply by the observed natural differences 
between patients. In this case, we can consider that all 
Table 1  Quality assessment for 
case series Quality assessment for case series
1 Case series collected in more than 1 center (i.e. a multicentric study)
2 Is the hypothesis/aim/objective of the study clearly described?
3 Are the inclusion and exclusion criteria (case definition) celarly reported?
4 Is there a clear definition of the outcomes reported?
5 Were data collected prospectively?
6 Is there an explicit statement that patients were recruited consecutively?
7 Are the main findings of the study clearly described?
8 Are outcomes stratified (i.e. by disease stage, abnormal test results, 
patient characteristics)?
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patients are part of the same larger pool. A fixed-effects 
meta-analysis is appropriate in which each patient is given 
approximately equal weight. However, with high heteroge-
neity, the studies differ by more than can be explained by 
intra-patients effects. This implies that there were differ-
ences in the patients studies, in the treatment interventions, 
or in the outcome measures. In this case, a random-effects 
meta-analysis is appropriate in which each study is given 
more equal weight.
All analyses were performed using STATA version 13 
(StataCorp. 2013. Stata Statistical Software: Release 13. 
College Station, TX: StataCorp LP).
Results
The search strategy identified 110 articles in Medline from 
1980 to the search date. They were selected, imported into 
Endnote, and the duplicates were removed. The removal 
of duplicates, non-English language works and of articles 
about other items rather than primary conservative surgical 
treatment for advanced laryngeal cancer yielded a total of 
71 publications. 25 studies out of 71 were excluded from 
our analysis because reporting report, including letters or 
reviews, or not including advanced T stage laryngeal cancer 
but focusing only and general tumour stage. Therefore, 46 
articles were considered for the qualitative systematic review 
whilst, only 21 out of 46, reporting on the outcomes of 1918 
patients, were included in the meta-analysis.
The various stages of systematically assessing the 
abstracts and reasons for exclusion from the review are 
described in Fig. 1.
As for their quality, as assessed by the quality assessment 
criteria outlined above, 10 papers scored six or seven, 10 
papers scored four or five and one paper scored three.
Of the included patients, 1448 and 470 patients were 
reported to have T3 and T4 tumour respectively, accordingly 
to the pathological AJCC classification [2].
The surgical procedures described in the 21 papers, 
included: transoral laser microsurgery (TLM), cricohyoidoe-
piglotto-pexy (CHEP), cricohyoidopexy (CHP), tracheohy-
oidoepiglotto-pexy (THIEP), tracheoepiglotto-pexy (THIP); 
supra tracheal partial laryngectomy (STLP), supracricoid 
partial laryngectomy (SCPL), horizontal partial laryngec-
tomy (HPL), as reported in Table 2.
Adjuvant radiotherapy (RT) was not systematically 
administered by authors to every patient to avoid its poten-
tial collateral effects on their functional outcomes [31, 39]. 
The presence of positive resection margins after open par-
tial surgery or patients with persistent tumour after transoral 
margins re-resection, large extra-laryngeal tumour extent, 
pathological report with presence of perineurial invasion and 
angioembolization, multiple positive lymph nodes and/or 
neck nodes with extra capsular spread (ECS) of the disease, 
represented the main conditions for adjuvant RT treatment 
indication.
Only three out of the 21 articles did not well specify indi-
cations and sites of adjuvant treatment [7, 34, 37]; on the 
other hand, the remaining 18 papers reported reasons and 
sites of post-operative RT. Table 2 summarises the num-
ber of patients who underwent adjuvant RT, where primary 
tumour and neck sites are reported separately.
Accordingly to our inclusion criteria, the follow-up dura-
tion time ranged from 12 to 120 months, with a median fol-
low-up of 60 months.
The pooled OS (overall survival) was 71% (95% CI 
64–78). Heterogeneity tests revealed significant heteroge-
neity (I2 = 90.4%) which is to be expected given the wide 
spectrum of operations, outcomes and follow-up times 
reported. The lowest OS rate was 49.80% [32], with two 
studies reporting 94 and 93.80% OS rates [34, 42]. The for-
est plot is shown in Fig. 2.
The pooled DFS (disease-free survival) was 79% (95% CI 
74–85) with significant heterogeneity (I2 = 89.7%). The low-
est DFS rate was 52.54% [32], with other two studies both 
reporting 93.75% of DFS [33, 42] and one study showing 
no recurrence event [35]. The forest plot is shown in Fig. 3.
Figures 4, 5 show forest forest plot by technique for OS 
and DFS, respectively. Here we divided surgical procedures 
into two different groups: (1) CLOSED techniques—TLM; 
vs. (2) OPEN techniques, including CHEP, CHP, THIEP, 
THIP, STLP, SCPL and HPL.
The pooled OS was the same in the two subgroups (het-
erogeneity between groups, p value of 0.518) with 69% (95% 
CI 59–79) pooled OS rate in the closed technique group and 
73% (95% CI 66–81) pooled OR rate in the open technique 
group. The pooled DFS was quite different in the two sub-
groups (heterogeneity between groups, p value of 0.118) 
with 76% (95% CI 69–83) pooled DSS rate in the closed 
technique group and 83% (95% CI 78–89) pooled DFS rate 
in the open technique group.
Discussion
Despite its efficacy as an oncologic procedure, total lar-
yngectomy (TL) implies complete loss of the larynx and 
represents a devastating event with significant subsequent 
diminution of quality of life for many individuals. Mod-
ern voice restoration procedures, have greatly improved 
the quality of life after TL but, since the 1980s it became 
apparent that in selected cases removal of the entire larynx 
was not necessary. In fact, conservation surgery complies 
with oncologic surgical principles and it has been shown 
that long-term survival rates are comparable to TL on well 
selected same advanced laryngeal lesions. In this respect, 
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Fig. 1  This flow chart illustrates the process that was used to select articles for the review
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a wide variety of treatment options are available and all 
of them provide similar survival outcomes, where con-
siderations of patients’ expectations and surgeons’ skills 
play a fundamental role in decision making for advanced T 
stage laryngeal tumours. An analysis of the National Can-
cer Data Base (NCDB) information on laryngeal cancer 
has demonstrated a surprising decrease in 5-year overall 
survival for laryngeal cancer from 1985 to 2001, from 68.1 
to 64.7%, contrary to the most other malignancies [43].
In general, there has been a move from surgery towards 
chemoradiation therapy in the management of advanced 
laryngeal cancer patients, in attempt to preserve laryngeal 
functions; however, nonsurgical preservation approach do 
not offer a survival advantage compared to TL [14], and 
due to the evidence of objective failures of preservation 
laryngeal protocols [44–50], conservative surgery has been 
increasingly considered for selected tumours [51].
In the panorama of available surgical conservative 
techniques, both transoral and open conservative options, 
require specific expertise to ensure reproducible results.
TLM is known to be usually feasible for early glottic 
tumours, but there are evidences regarding the use of TLM 
for T3 glottic cancers with reported 5-year overall (53.1%), 
disease-specific (70.2%) and laryngectomy-free (62.3%) 
survivals which make this technique indication still contro-
versial [4, 52]. TLM has also demonstrated to be suitable 
for T3 supraglottic tumours with limited paraglottic or pre-
epiglottic space invasion and also in some T4 cases with 
limited extension to tongue base or hypopharyngeal inva-
sion. Accordingly, Hinni et al. [32] demonstrated a laryngeal 
preservation rate of 86% and a 5-year overall and disease-
free survival of 50 and 53%, respectively; Rudert at el [53] 
confirmed a 5-year overall survival of 47% and Motta of 77% 
for T3 patients with a laryngeal preservation rate of 93.7% 
[54]. Vilaseca et al. [41] published one of the largest series 
on 154 patients with T3–T4 supraglottic cancers treated with 
TLM, by obtaining an OS and DFS rates ranging from 67 
to 90%, with a laryngeal preservation percentage up to 85.
Literature concludes that TLM can be considered an 
established therapeutic option for selected advanced T stage 
Table 2  Included studies with key results
TLM transoral laser microsurgery, HPL horizontal partial laryngectomy, SCPL supracricohyoid partial laryngectomy, CHEP cricohyoidoe-
piglottopexy, CHP cricohyoidopexy, STPL supratracheal partial laryngectomy, THIEP tracheohyoidoepiglottopexy, THIP tracheohyoidopexy, 
CPL conservative partial laryngectomy, CAU cricoarytenoid unit
*Quality score
**Patients number
Authors QS* Year Pts n.** Procedures Adjuvant radiotherapy (RT) DFS (%) OS (%)
Primary Neck
Blanch [24] 5 2011 26 TLM 1 6 80.40 71
Breda [25] 5 2015 43 TLM 5 16 72.70 83.5
Bron [26] 5 2005 16 HPL 3 7 83 80.26
Bussu [7] 7 2013 43 CHP 15 patients (undetermined site) 70 68
Canis [27] 5 2013 79 TLM 5 26 71.80 55.80
Canis [28] 7 2013 159 TLM 55 84 81 59
Cho [29] 4 2010 35 SCPL (CHEP–CHP) THIP–THIEP 0 7 82 78
Dufour [30] 5 2004 118 SCPL 4 24 91.40 58
Gallo [31] 6 2005 79 CHP–CHEP 10 0 85.60 75.30
Hinni [32] 7 2007 106 TLM 15 29 52.54 49.80
Nakayama [33] 3 2008 16 SCL (CHEP–CHP) 0 2 93.75 86
Pearson [34] 5 2003 16 TLM 5 patients (undetermined site) 87.50 94.0
Peretti [35] 5 2010 11 TLM 10 0 100 87.50
Peretti [36] 6 2016 56 TLM 15 11 87 63.30
Qian [37] 6 2014 20 CPL All of them underwent adjuvant RT 53 55.90
Rizzotto [38] 6 2015 101 THIP,THIEP 24 7 65.90 77.70
Succo [39] 6 2015 120 THIEP+CAU, THIP+CAU 28 13 91.70 63.81
Succo [40] 6 2016 555 CHEP,CHP, THIP,THIEP 72 123 92.80 84.60
Vilaseca [4] 6 2010 147 TLM 25 37 70.20 53.10
Vilaseca [41] 5 2016 154 TLM 46 58 67.60 55.60
Wilkie [42] 5 2015 16 TLM 3 15 93.75 93.80
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laryngeal tumours, based on good oncologic, functional and 
economic considerations with an organ preservation rate 
over 60% in the vast majority of cases [4, 16, 55, 56].
In case of laryngeal tumours involving or originating 
from the anterior commissure (AC), difficulties in treatment 
could be related to tumour exposure and technical limita-
tions of lack of perpendicular laser tool, which could be 
minimised by an enlarged resection and advanced surgical 
experience with TLM which allow the achievement of com-
parable oncologic and functional results with low morbidity 
[24, 34].
On the other hand, since Piquet and Chavalier [57] 
supracricoid laryngectomy has gained international accept-
ance, ensuring a reproducible and shared 5-year overall 
survival rate for all stages between 75 and 95% [26, 29, 31, 
33, 40, 58], together with a preservation successful rate in 
about 80% of cases [59, 60].
Given the lack of randomised control trials or even pro-
spective studies in the topic of selection criteria for the use 
of different conservative surgical procedures as primary 
treatment for advanced laryngeal cancers, this study might 
offer a potential available evidence on the question. Despite 
several reports available in literature, all of them are mainly 
focused on one out of the several existing conservative tech-
niques, whilst this study offers a systematic review of pub-
lished articles and statistically robust results.
The finding of 79% loco-regional control rate in over 1918 
patients and about 80% of preservation rate gives credence 
Fig. 2  Forest plot of overall survival (OS) for all patients, with pooled estimate and confidence intervals calculated using the DerSimonian Laird 
(random effects) model
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to the oncologic efficacy of these conservative surgical pro-
cedures. About 60% of patients were treated for advanced 
glottic cancers (n = 1134), whilst the remaining cases where 
advanced supraglottic tumours (n = 774). Although neck dis-
ease was not always clearly described and analysed, neck 
dissection was always recommended for supraglottic lesions 
and in case of clinical evidence of neck disease, but it was 
not possible to carry on statistical analysis due to lack of 
accurate data collection. It is obvious from our results that 
conservative surgical approach is a valid option for advanced 
(T3–T4) laryngeal lesions primary treatment, but due to the 
lower OS and DFS rate for the closed techniques (69 and 
76%) compared to open procedures (73 and 83%, p value 
not statistically significant), efforts should be made on 
individual patients’ characteristics and expectations, and on 
available surgical skills and expertise for treatment.
Bussu et al. [7] in their series of patients with advanced 
laryngeal cancer, compared the oncological outcomes of 
3 different therapeutic modalities [total laryngectomy, 
radiochemotherapy, or cricohyoidopexy (CHP)]. They 
observed a trend indicating better results in patients who 
underwent total laryngectomy vs those who underwent 
surgical and nonsurgical organ preservation strategies 
with respect to OS (90 vs 81 vs 68%, respectively, at 2 
years, p = 0.07, Wilcoxon test) and DSS (92 vs 86 vs 72%, 
respectively, at 2 years, p = 0.08). In particular, among 
the cT4a cases, (2-year OS 93 vs 68% for CHP and 54% 
for nonsurgical treatment, p = 0.031) and for cT3 (2-year 
Fig. 3  Forest plot of disease-free survival (DFS) for all patients, with pooled estimate and confidence intervals calculated using the DerSimo-
nian Laird (random effects) model
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OS: 94% for total laryngectomy, 90% for CHP, 60% for 
radiochemotherapy, p = 0.0004) a better OS and DSS were 
observed for patients treated by total laryngectomy. It is 
easy to understand that demolitive surgery provides better 
control of disease, although incurring a higher percent-
age of laryngeal function impairment and late sequelae 
that hamper patients’ quality of life. The current trend for 
management of laryngeal cancer indicates that pursuing 
therapeutic options able to preserve laryngeal functionality 
provides the best quality of life for patients maintaining 
good oncological results.
In this perspective, post-operative irradiation has been 
reported to increase the rate of laryngeal preservation [35], 
accordingly to its previous mentioned indications. How-
ever, adjuvant RT is usually discouraged on the primary 
tumour site after partial laryngeal surgery because of its 
potential unfavourable functional late effects, including its 
rate in delaying patients recovery. In our meta-analysis, 
Fig. 4  Forest plot of overall survival (OS) sorted into two groups of treatment, with pooled estimate and confidence intervals calculated using 
the DerSimonian Laird (random effects) model
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crucial points were represented by positive resection 
margins. Closed techniques differed from the open ones 
in proposing a second surgical revisions in case of first 
pathological report indicative for presence of invasive can-
cers on resection margins; while, in the case of equivocal 
margins second procedures were not routinely performed. 
Only after a second pathological report indicative for deep 
positive margins, adjuvant RT was administered on the pri-
mary tumour site [35, 36, 42]. This is the reason why close 
cooperation with expert pathologists is of overwhelming 
importance. In accordance with these strict indications for 
adjuvant treatment, some authors such as Wilkie, Pearson 
and Peretti [34–36, 42] gained the highest rates of OS and 
DFS, in contrast to Hinni et al. [32], thus highlighting that 
TLM might reach excellent results when accurate selection 
of patients is made. Whilst, articles about closed technique 
showed less homogeneity in their outcome results, papers 
dealing with open procedures obtained more comparable 
Fig. 5  Forest plot of disease-free survival (DFS) sorted into two groups of treatment, with pooled estimate and confidence intervals calculated 
using the DerSimonian Laird (random effects) model
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data. This might be due to, not only to a longer surgical 
experience, but also to the presence of more consolidate 
indications for adjuvant radiotherapy, in comparison to 
those applied in TLM, so far, confirmed by a lower recur-
rence incidence rate (p = 0.118).
Although partial laryngectomies applicability to the man-
agement of locally advanced laryngeal carcinomas is gain-
ing progressive consent among clinicians, upon our results, 
large T3 and more advanced pT4a tumours require several 
considerations to absolutely compare partial surgery radi-
cality to that resulting from total laryngectomy procedure 
and primary (chemo)radiotherapy [27, 28, 39]. Pearson [34] 
has shown how the site of origin and T stage, despite they 
represent important considerations, do not represent over-
riding factors for TLM. Canis [27, 28] has demonstrated 
how TLM with/without adjuvant RT is a valid strategy for 
organ preservation and is an attractive therapeutic option 
even in locally advanced laryngeal cancers. Accordingly, 
open access supports en bloc tumour removal but, arytenoids 
cartilage fixation, posterior commissure invasion, cricoid 
cartilage invasion and extra-laryngeal cancer spread do still 
represent major contraindications for partial procedure indi-
cations [33].
A very important secondary endpoint is the functional 
outcome, however the data was not always specified in the 
mentioned papers making impossible any comparative anal-
ysis among TLM and OPL. In fact, not every patient treated 
conservatively by both TLM or OPL have a complete res-
toration of laryngeal function, even if this represent a goal 
reached by the great majority of them.
Conclusion
The aim of this review was to show that evidence for sur-
gical conservative strategies still remain low, despite the 
encouraging results over the last fifteen years. Future per-
spective randomised trials with comparable cohorts should 
aim to improve our levels of evidence for treatment decision 
making.
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